AstraZeneca opens Lumi-NHL study in heavily pretreated B-cell lymphoma
AstraZeneca has launched AZD4512 into a phase 1/2 trial aimed at adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a population that has often exhausted standard therapy by the time investigational treatment becomes available. The study, known as Lumi-NHL, is open-label, global, and multicenter, and it is designed to examine AZD4512 as monotherapy and in combination with other anticancer agents. A second module pairs the drug with surovatamig in relapsed or refractory large B-cell lymphoma, extending the program beyond dose finding into combination development.
The study is structured around a familiar but difficult oncology problem: patients whose disease has already resisted anti-CD20 therapy, chemotherapy, and often cellular or bispecific approaches. In that setting, trial design matters because eligibility is not broad by accident; it is narrow because the disease biology has already announced itself as treatment-resistant. Adults enrolled in Lumi-NHL must have measurable disease by Lugano 2014 criteria and an ECOG performance status of 2 or better, with organ and marrow function sufficient to tolerate another systemic intervention.
Two development paths for a single investigational program
Lumi-NHL uses two modules to answer different clinical questions. Module 1 evaluates AZD4512 monotherapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma who have already received at least two prior lines of therapy. Backfill in that module narrows the population further to selected large B-cell lymphoma subtypes and mantle cell lymphoma, reflecting the practical need to learn whether the drug has a usable activity and safety profile in specific histologies rather than in a loosely defined basket.
Module 2 moves in a different direction. It tests AZD4512 together with surovatamig in relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, grade 3b follicular lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, and transformed indolent B-cell lymphoma. Patients with prior CD19-directed therapy must demonstrate preserved CD19 expression locally after that treatment, a biologically important gatekeeper step for any regimen that relies on CD19 biology. Loss of target expression can convert an apparently eligible patient into a poor match for another CD19-directed strategy.
The trial’s focus on CD19 expression speaks to the central tension in advanced B-cell lymphoma: once a tumor has survived multiple lines of therapy, it may have remodeled the antigenic surface that earlier treatments depended on. If CD19 remains present, combination therapy may still have a plausible route into the malignant clone. If it is absent, the therapeutic logic collapses before the first dose.
Safety filters define the real-world limits of enrollment
The exclusion criteria are extensive, and they reveal the risks that come with advancing a new oncology agent into a fragile population. Patients with active central nervous system involvement from lymphoma cannot enroll, and neither can those with recent CAR-T therapy, recent T-cell engager therapy, recent investigational drugs, recent systemic anticancer therapy, or recent curative radiation. The protocol also excludes patients with major recent surgery, strong CYP3A inhibitor exposure near dosing, QTc-prolonging drugs close to treatment, unresolved grade 2 or higher adverse events from prior therapy, active infection, serious uncontrolled medical illness, or a history or suspicion of significant interstitial lung disease or pneumonitis.
Previous dosing with AZD4512 is also disqualifying. For a first-in-human or early-phase program, that restriction is standard, but it also signals how carefully the sponsor is trying to avoid confounding between prior exposure and current toxicity or pharmacologic interpretation.
One sentence captures the operational reality of the study better than any brochure language could: this is a trial for patients with very few remaining standard options, but not for patients who are already too medically unstable to withstand experimental therapy.
Enrollment spans multiple continents and multiple lymphoma programs
The estimated enrollment is 164 participants, with a study start date of September 24, 2025, and estimated primary completion in July 2028. Final study completion is projected for February 2029. The protocol lists 23 locations across the United States, Australia, China, Italy, Japan, South Korea, Taiwan, and the United Kingdom, suggesting a broad recruitment strategy designed to capture a rare and dispersed population.
In the United States, sites include California, Florida, Minnesota, New York, Tennessee, Ohio, and South Carolina, although some locations are marked suspended or withdrawn while others remain recruiting. Outside the United States, the study is active or planned across major academic centers in Melbourne, Bologna, Milan, London, Newcastle upon Tyne, Seoul, Taipei, Tokyo-area centers, and sites in China. That geographic spread is important in lymphoma development because referral patterns differ, prior-treatment access differs, and the pool of patients who remain eligible after CAR-T, bispecific therapy, or transplant can be unexpectedly small at any single center.
Why the design matters for relapsed B-cell lymphoma
The choice to study AZD4512 in both monotherapy and combination settings reflects a common early-phase strategy in lymphoma drug development. Monotherapy can reveal whether the agent has intrinsic activity and define a safety ceiling. Combination therapy then asks whether a second mechanism can deepen responses in tumors that have already learned to survive single-pathway pressure. In B-cell lymphoma, especially aggressive histologies, the biologic rationale for combination work is strong because resistance often emerges through multiple escape routes at once: antigen loss, altered signaling, microenvironmental protection, and clonal evolution under treatment pressure.
Eligibility rules show how much the field has changed. Patients must have progressed after anti-CD20 therapy and at least one systemic chemotherapy regimen, and they must have considered or been ineligible for CAR-T, T-cell engager therapy, and stem cell transplant. In other words, Lumi-NHL is not competing with first-line therapy; it is being positioned after the most established salvage options have either failed or become unavailable.
For patients and clinicians, the trial represents a chance to evaluate whether AZD4512 can still exert a meaningful effect in disease that has already outlasted several modern therapies. For the development program, the unanswered questions are more basic and more demanding: how much activity will emerge in each module, what toxicities will limit dosing, and whether the addition of surovatamig changes the therapeutic balance enough to justify further expansion. Those answers will not come from the registration page. They will come only after the first cohorts begin to separate safety from futility, and after the lymphoma itself shows whether it can still be pushed back by a new mechanism.